603707.SHG Nanjing King-friend Biochemical Pharmaceutical Co Ltd
- Market cap
- CNY 13.9B
- P/E
- 33.0x
- P/B
- 1.89x
- ROE
- 5.2%
- Dividend yield
- 1.57%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603707.SHG undervalued?
Graham number603707.SHG trades 66.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanjing King-friend Biochemical Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Nanjing King-friend Biochemical Pharmaceutical Co Ltd yet.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-hepa…
Full company profileNanjing King-friend Biochemical Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 582M | 1.11B | 1.70B | 2.47B | 2.91B | 3.69B | 3.71B | 3.93B | 3.92B | 3.99B | 4.01B |
| Gross Profit | 245M | 516M | 840M | 1.27B | 1.68B | 2.08B | 1.93B | 659M | 1.81B | 1.57B | 1.40B |
| Operating Income | 161M | 352M | 460M | 668M | 877M | 1.18B | 1.17B | -295M | 994M | 581M | 403M |
| EBITDA | 181M | 382M | 491M | 717M | 1.01B | 1.32B | 1.16B | -178M | 1.14B | 998M | 452M |
| Net Income | 257M | 314M | 425M | 605M | 806M | 1.06B | 1.09B | -189M | 826M | 582M | 364M |
| EPS | 0.19 | 0.21 | 0.35 | 0.38 | 0.51 | 0.67 | 0.68 | -0.12 | 0.50 | 0.36 | 0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 1.52B | 2.69B | 3.40B | 5.08B | 7.72B | 8.22B | 10.0B | 9.52B | 9.51B | 10.3B | 10.6B |
| Total Liabilities | 208M | 642M | 981M | 2.07B | 3.98B | 2.81B | 3.84B | 3.73B | 3.02B | 3.44B | 3.61B |
| Shareholders' Equity | 1.31B | 2.05B | 2.42B | 2.97B | 3.72B | 5.38B | 6.17B | 5.80B | 6.49B | 6.90B | 7.01B |
| Cash & Short-term Investments | 266M | 73.1M | 435M | 421M | 1.34B | 918M | 1.39B | 1.89B | 2.08B | 1.39B | 1.44B |
| Total Debt | 120M | 323M | 320M | 1.37B | 3.26B | 2.05B | 2.96B | 2.09B | 2.06B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -287M | -235M | 62.4M | -841M | -566M | 684M | 595M | 1.62B | 1.50B | 1.18B | - |
| Capital Expenditure | 72.5M | 81.1M | 82.8M | 115M | 294M | 441M | 470M | 419M | 507M | 560M | 368M |
| Free Cash Flow | -359M | -316M | -20.4M | -957M | -860M | 243M | 125M | 1.20B | 994M | 623M | 1.18B |
| Ratios | |||||||||||
| ROE | 19.6% | 15.3% | 17.5% | 20.4% | 21.7% | 19.7% | 17.7% | -3.3% | 12.7% | 8.4% | 5.2% |
| ROA | 16.9% | 11.7% | 12.5% | 11.9% | 10.4% | 12.9% | 10.9% | -2.0% | 8.7% | 5.6% | 3.4% |
| Net Profit Margin | 44.2% | 28.2% | 25.0% | 24.5% | 27.7% | 28.7% | 29.4% | -4.8% | 21.1% | 14.6% | 9.1% |
| Debt to Equity | 0.09x | 0.16x | 0.13x | 0.46x | 0.88x | 0.38x | 0.48x | 0.36x | 0.32x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.57%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 37.6%
- Ex-dividend date
- Jun 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 218M | 0.14 | 37.6% |
| 2024 | CNY 213M | 0.13 | 25.8% |
| 2023 | CNY 248M | 0.16 | - |
| 2022 | CNY 187M | 0.12 | 17.1% |
| 2021 | CNY 140M | 0.09 | 13.3% |
| 2020 | CNY 216M | 0.14 | 26.7% |
| 2019 | CNY 82.9M | 0.05 | 13.7% |
| 2018 | CNY 73.1M | 0.06 | 17.2% |
| 2017 | CNY 3.00M | 0.00 | 1.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jul 11, 2022.
Who owns Nanjing King-friend Biochemical Pharmaceutical Co Ltd
- Insiders 73.68%
- Institutions 1.76%
- Public & others 24.56%
- Shares outstanding 1.62B
- Free float 455M
Nanjing King-friend Biochemical Pharmaceutical Co Ltd company profile
- Company name
- Nanjing King-friend Biochemical Pharmaceutical Co Ltd
- Ticker
- 603707.SHG
- ISIN
- CNE100002WP3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,558
- Fiscal year end
- December
- Address
- No. 16 Xuefu Road, Nanjing, China, 210032
- Phone
- 86 25 8699 0701
- Website
- nkf-pharma.com
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injection, liraglutide injection, daptomycin for injection, pantoprazole sodium for injection, reganoxone injection, leucovorin calcium for injection, bivalirudin for injection, micafungin for injection, ducalciferol injection, fondaparinux sodium injection, and cisatracurium besylate injection. In addition, the company offers process development and preparation, process optimization, registration and validation approval, and manufacturing, as well as customized research and development, and manufacturing for commercialization. Its injection products are used in anticoagulation, anti-tumor, and cardiovascular disease areas, surgical anesthesia, antibacterial infection, and contrast imaging. The company was founded in 2000 and is based in Nanjing, China.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd management
5- Mr. Tang YongqunGM & Chairman · born 1976
- Dr. Huang XiweiDeputy GM, Secretary & Employee Representative Director · born 1970
- Ms. Wu GuipingDeputy General Manager · born 1963
- Ms. Lamei ChenChief Financial Officer · born 1984
- Xiaomei GuAccounting Supervisor